$SLXP Insider Trading
FREE EMAIL WATCHDOG
Get free email notifications about insider trading in SALIX PHARMACEUTICALS LTD.
- Your email is safe with us.
- The service is free and you can unsubscribe at any time.
General | Insiders | Insider Transactions | Monthly Overview | Weekly Overview
Overview of all insider trading transactions in SALIX PHARMACEUTICALS LTD. Get notifications about new insider transactions in SALIX PHARMACEUTICALS LTD for free.
Page: < prev 1 2 3 4 5 6 7 ... 8 next >
Date | Ticker | Company | Owner | Relationship | Transaction | Code | Cost ($) | Shares | Transaction Value ($) | Total Shares | % Holdings |
---|---|---|---|---|---|---|---|---|---|---|---|
Dec 17 2010 | SLXP | SALIX PHARMACEUTIC ... | CHAPPELL JOHN F | Director | Gift | G | 0.00 | 10,000 | 0 | 10,000 | 0 to 10 K |
Dec 17 2010 | SLXP | SALIX PHARMACEUTIC ... | CHAPPELL JOHN F | Director | Gift | G | 0.00 | 5,600 | 0 | 397,704 | 403.3 K to 397.7 K (-1.39 %) |
Dec 17 2010 | SLXP | SALIX PHARMACEUTIC ... | CHAPPELL JOHN F | Director | Gift | G | 0.00 | 10,000 | 0 | 403,304 | 413.3 K to 403.3 K (-2.42 %) |
Dec 03 2010 | SLXP | SALIX PHARMACEUTIC ... | D ALONZO THOMAS | Director | Buy | P | 44.80 | 500 | 22,399 | 500 | 0 to 500 |
Nov 16 2010 | SLXP | SALIX PHARMACEUTIC ... | CHAPPELL JOHN F | Director | Sell | S | 41.96 | 22,500 | 944,208 | 413,304 | 435.8 K to 413.3 K (-5.16 %) |
Nov 24 2010 | SLXP | SALIX PHARMACEUTIC ... | FRANCO RICHARD A | Director | Sell | S | 43.80 | 2,500 | 109,500 | 34,334 | 36.8 K to 34.3 K (-6.79 %) |
Nov 12 2010 | SLXP | SALIX PHARMACEUTIC ... | Forbes William P | V.P. Research& Deve ... | Option Exercise | M | 17.53 | 10,000 | 175,300 | 80,000 | |
Nov 12 2010 | SLXP | SALIX PHARMACEUTIC ... | Forbes William P | V.P. Research& Deve ... | Sell | S | 40.01 | 10,000 | 400,053 | 57,657 | 67.7 K to 57.7 K (-14.78 %) |
Nov 12 2010 | SLXP | SALIX PHARMACEUTIC ... | Forbes William P | V.P. Research& Deve ... | Buy | M | 17.53 | 10,000 | 175,300 | 67,657 | 57.7 K to 67.7 K (+17.34 %) |
Oct 21 2010 | SLXP | SALIX PHARMACEUTIC ... | CHAPPELL JOHN F | Director | Sell | S | 39.42 | 100 | 3,942 | 435,804 | 435.9 K to 435.8 K (-0.02 %) |
Oct 21 2010 | SLXP | SALIX PHARMACEUTIC ... | CHAPPELL JOHN F | Director | Sell | S | 38.89 | 24,900 | 968,473 | 435,904 | 460.8 K to 435.9 K (-5.40 %) |
Oct 12 2010 | SLXP | SALIX PHARMACEUTIC ... | D ALONZO THOMAS | Director | Buy | P | 38.00 | 260 | 9,880 | 260 | 0 to 260 |
Sep 23 2010 | SLXP | SALIX PHARMACEUTIC ... | LOGAN CAROLYN J | President & CEO | Sell | S | 42.35 | 14,000 | 592,857 | 752,007 | 766 K to 752 K (-1.83 %) |
Sep 16 2010 | SLXP | SALIX PHARMACEUTIC ... | Forbes William P | V.P. Research& Deve ... | Sell | S | 40.50 | 10,695 | 433,108 | 57,657 | 68.4 K to 57.7 K (-15.65 %) |
Sep 13 2010 | SLXP | SALIX PHARMACEUTIC ... | CHAPPELL JOHN F | Director | Sell | S | 40.92 | 4,676 | 191,342 | 460,804 | 465.5 K to 460.8 K (-1.00 %) |
Sep 09 2010 | SLXP | SALIX PHARMACEUTIC ... | CHAPPELL JOHN F | Director | Sell | S | 40.42 | 4,000 | 161,680 | 465,480 | 469.5 K to 465.5 K (-0.85 %) |
Sep 07 2010 | SLXP | SALIX PHARMACEUTIC ... | CHAPPELL JOHN F | Director | Sell | S | 39.40 | 4,000 | 157,600 | 469,480 | 473.5 K to 469.5 K (-0.84 %) |
Sep 08 2010 | SLXP | SALIX PHARMACEUTIC ... | FRANCO RICHARD A | Director | Sell | S | 40.00 | 6,500 | 260,000 | 36,834 | 43.3 K to 36.8 K (-15.00 %) |
Aug 30 2010 | SLXP | SALIX PHARMACEUTIC ... | FRANCO RICHARD A | Director | Sell | S | 39.01 | 6,500 | 253,543 | 43,334 | 49.8 K to 43.3 K (-13.04 %) |
Jul 21 2010 | SLXP | SALIX PHARMACEUTIC ... | Sirgo Mark A | Director | Grant | A | 0.00 | 4,360 | 0 | 35,746 | 31.4 K to 35.7 K (+13.89 %) |
Jul 21 2010 | SLXP | SALIX PHARMACEUTIC ... | FRANCO RICHARD A | Director | Grant | A | 0.00 | 4,360 | 0 | 49,834 | 45.5 K to 49.8 K (+9.59 %) |
Jul 21 2010 | SLXP | SALIX PHARMACEUTIC ... | KEANE WILLIAM P | Director | Grant | A | 0.00 | 4,360 | 0 | 38,933 | 34.6 K to 38.9 K (+12.61 %) |
Jul 21 2010 | SLXP | SALIX PHARMACEUTIC ... | D ALONZO THOMAS | Director | Grant | A | 0.00 | 4,360 | 0 | 65,680 | 61.3 K to 65.7 K (+7.11 %) |
Jul 21 2010 | SLXP | SALIX PHARMACEUTIC ... | CHAPPELL JOHN F | Director | Grant | A | 0.00 | 4,360 | 0 | 473,480 | 469.1 K to 473.5 K (+0.93 %) |
Jul 21 2010 | SLXP | SALIX PHARMACEUTIC ... | Reeth Mark D | Gen Counsel&VP Corp ... | Grant | A | 0.00 | 7,930 | 0 | 43,678 | 35.7 K to 43.7 K (+22.18 %) |
Jul 21 2010 | SLXP | SALIX PHARMACEUTIC ... | LOGAN CAROLYN J | President & CEO | Grant | A | 0.00 | 65,560 | 0 | 766,007 | 700.4 K to 766 K (+9.36 %) |
Jul 21 2010 | SLXP | SALIX PHARMACEUTIC ... | Forbes William P | V.P. Research& Deve ... | Grant | A | 0.00 | 15,055 | 0 | 68,352 | 53.3 K to 68.4 K (+28.25 %) |
Jul 21 2010 | SLXP | SALIX PHARMACEUTIC ... | DERBYSHIRE ADAM C | EVP Finance/CFO | Grant | A | 0.00 | 19,520 | 0 | 119,277 | 99.8 K to 119.3 K (+19.57 %) |
Jul 14 2010 | SLXP | SALIX PHARMACEUTIC ... | CHAPPELL JOHN F | Director | Sell | S | 41.08 | 4,638 | 190,512 | 469,120 | 473.8 K to 469.1 K (-0.98 %) |
Jul 14 2010 | SLXP | SALIX PHARMACEUTIC ... | CHAPPELL JOHN F | Director | Sell | S | 40.56 | 20,062 | 813,669 | 473,758 | 493.8 K to 473.8 K (-4.06 %) |
Jul 14 2010 | SLXP | SALIX PHARMACEUTIC ... | CHAPPELL JOHN F | Director | Sell | S | 39.98 | 300 | 11,994 | 493,820 | 494.1 K to 493.8 K (-0.06 %) |
Jul 06 2010 | SLXP | SALIX PHARMACEUTIC ... | DERBYSHIRE ADAM C | EVP Finance/CFO | Payment of Exercise | F | 39.03 | 8,614 | 336,204 | 99,757 | 108.4 K to 99.8 K (-7.95 %) |
Jul 06 2010 | SLXP | SALIX PHARMACEUTIC ... | D ALONZO THOMAS | Director | Payment of Exercise | F | 39.03 | 3,040 | 118,651 | 61,320 | 64.4 K to 61.3 K (-4.72 %) |
Jul 06 2010 | SLXP | SALIX PHARMACEUTIC ... | Forbes William P | V.P. Research& Deve ... | Payment of Exercise | F | 39.03 | 7,586 | 296,082 | 53,297 | 60.9 K to 53.3 K (-12.46 %) |
Jul 06 2010 | SLXP | SALIX PHARMACEUTIC ... | LOGAN CAROLYN J | President & CEO | Payment of Exercise | F | 39.03 | 37,994 | 1,482,906 | 700,447 | 738.4 K to 700.4 K (-5.15 %) |
Jul 06 2010 | SLXP | SALIX PHARMACEUTIC ... | KEANE WILLIAM P | Director | Payment of Exercise | F | 39.03 | 4,500 | 175,635 | 34,573 | 39.1 K to 34.6 K (-11.52 %) |
Jul 06 2010 | SLXP | SALIX PHARMACEUTIC ... | Sirgo Mark A | Director | Payment of Exercise | F | 39.03 | 3,770 | 147,143 | 31,386 | 35.2 K to 31.4 K (-10.72 %) |
Jul 06 2010 | SLXP | SALIX PHARMACEUTIC ... | FRANCO RICHARD A | Director | Payment of Exercise | F | 39.03 | 3,770 | 147,143 | 45,474 | 49.2 K to 45.5 K (-7.66 %) |
Jul 06 2010 | SLXP | SALIX PHARMACEUTIC ... | Reeth Mark D | Gen Counsel&VP Corp ... | Payment of Exercise | F | 39.03 | 3,536 | 138,010 | 35,748 | 39.3 K to 35.7 K (-9.00 %) |
Jun 15 2010 | SLXP | SALIX PHARMACEUTIC ... | Reeth Mark D | Gen Counsel&VP Corp ... | Sell | S | 36.24 | 4,278 | 155,030 | 39,284 | 43.6 K to 39.3 K (-9.82 %) |
May 19 2010 | SLXP | SALIX PHARMACEUTIC ... | Reeth Mark D | Gen Counsel&VP Corp ... | Sell | S | 37.38 | 3,377 | 126,226 | 43,562 | 46.9 K to 43.6 K (-7.19 %) |
May 13 2010 | SLXP | SALIX PHARMACEUTIC ... | LOGAN CAROLYN J | President & CEO | Option Exercise | M | 1.13 | 40,000 | 45,200 | 0 | |
May 13 2010 | SLXP | SALIX PHARMACEUTIC ... | LOGAN CAROLYN J | President & CEO | Buy | M | 1.13 | 40,000 | 45,200 | 738,441 | 698.4 K to 738.4 K (+5.73 %) |
May 05 2010 | SLXP | SALIX PHARMACEUTIC ... | CHAPPELL JOHN F | Director | Sell | S | 40.66 | 25,000 | 1,016,520 | 494,120 | 519.1 K to 494.1 K (-4.82 %) |
May 05 2010 | SLXP | SALIX PHARMACEUTIC ... | FRANCO RICHARD A | Director | Sell | S | 40.22 | 5,000 | 201,100 | 49,244 | 54.2 K to 49.2 K (-9.22 %) |
May 05 2010 | SLXP | SALIX PHARMACEUTIC ... | Reeth Mark D | Gen Counsel&VP Corp ... | Payment of Exercise | F | 40.15 | 1,623 | 65,163 | 46,939 | 48.6 K to 46.9 K (-3.34 %) |
Apr 16 2010 | SLXP | SALIX PHARMACEUTIC ... | Forbes William P | V.P. Research& Deve ... | Option Exercise | M | 17.53 | 10,000 | 175,300 | 90,000 | |
Apr 16 2010 | SLXP | SALIX PHARMACEUTIC ... | Forbes William P | V.P. Research& Deve ... | Sell | S | 40.03 | 10,000 | 400,251 | 60,883 | 70.9 K to 60.9 K (-14.11 %) |
Apr 16 2010 | SLXP | SALIX PHARMACEUTIC ... | Forbes William P | V.P. Research& Deve ... | Buy | M | 17.53 | 10,000 | 175,300 | 70,883 | 60.9 K to 70.9 K (+16.42 %) |
Apr 05 2010 | SLXP | SALIX PHARMACEUTIC ... | Forbes William P | V.P. Research& Deve ... | Sell | S | 38.00 | 1,879 | 71,402 | 60,883 | 62.8 K to 60.9 K (-2.99 %) |
Mar 18 2010 | SLXP | SALIX PHARMACEUTIC ... | CHAPPELL JOHN F | Director | Sell | S | 30.50 | 25,000 | 762,430 | 519,120 | 544.1 K to 519.1 K (-4.59 %) |
Feb 23 2010 | SLXP | SALIX PHARMACEUTIC ... | LOGAN CAROLYN J | President & CEO | Option Exercise | M | 1.13 | 35,000 | 39,550 | 40,000 | |
Feb 23 2010 | SLXP | SALIX PHARMACEUTIC ... | LOGAN CAROLYN J | President & CEO | Gift | G | 0.00 | 520 | 0 | 3,770 | 3.3 K to 3.8 K (+16.00 %) |
Feb 23 2010 | SLXP | SALIX PHARMACEUTIC ... | LOGAN CAROLYN J | President & CEO | Gift | G | 0.00 | 520 | 0 | 3,770 | 3.3 K to 3.8 K (+16.00 %) |
Feb 23 2010 | SLXP | SALIX PHARMACEUTIC ... | LOGAN CAROLYN J | President & CEO | Gift | G | 0.00 | 520 | 0 | 698,441 | 699 K to 698.4 K (-0.07 %) |
Feb 23 2010 | SLXP | SALIX PHARMACEUTIC ... | LOGAN CAROLYN J | President & CEO | Gift | G | 0.00 | 520 | 0 | 698,961 | 699.5 K to 699 K (-0.07 %) |
Feb 23 2010 | SLXP | SALIX PHARMACEUTIC ... | LOGAN CAROLYN J | President & CEO | Buy | M | 1.13 | 35,000 | 39,550 | 699,481 | 664.5 K to 699.5 K (+5.27 %) |
Feb 04 2010 | SLXP | SALIX PHARMACEUTIC ... | Sirgo Mark A | Director | Payment of Exercise | F | 29.26 | 1,550 | 45,353 | 35,156 | 36.7 K to 35.2 K (-4.22 %) |
Jan 21 2010 | SLXP | SALIX PHARMACEUTIC ... | Sirgo Mark A | Director | Buy | P | 27.09 | 200 | 5,418 | 36,706 | 36.5 K to 36.7 K (+0.55 %) |
Jan 21 2010 | SLXP | SALIX PHARMACEUTIC ... | Sirgo Mark A | Director | Buy | P | 27.89 | 200 | 5,578 | 36,506 | 36.3 K to 36.5 K (+0.55 %) |
Dec 28 2009 | SLXP | SALIX PHARMACEUTIC ... | Forbes William P | V.P. Research& Deve ... | Sell | S | 25.00 | 5,000 | 125,000 | 62,762 | 67.8 K to 62.8 K (-7.38 %) |
Dec 16 2009 | SLXP | SALIX PHARMACEUTIC ... | LOGAN CAROLYN J | President & CEO | Gift | G | 0.00 | 550 | 0 | 3,250 | 2.7 K to 3.3 K (+20.37 %) |
Dec 16 2009 | SLXP | SALIX PHARMACEUTIC ... | LOGAN CAROLYN J | President & CEO | Gift | G | 0.00 | 550 | 0 | 3,250 | 2.7 K to 3.3 K (+20.37 %) |
Dec 16 2009 | SLXP | SALIX PHARMACEUTIC ... | LOGAN CAROLYN J | President & CEO | Gift | G | 0.00 | 550 | 0 | 664,481 | 665 K to 664.5 K (-0.08 %) |
Dec 16 2009 | SLXP | SALIX PHARMACEUTIC ... | LOGAN CAROLYN J | President & CEO | Gift | G | 0.00 | 550 | 0 | 665,031 | 665.6 K to 665 K (-0.08 %) |
Dec 14 2009 | SLXP | SALIX PHARMACEUTIC ... | LOGAN CAROLYN J | President & CEO | Option Exercise | M | 1.13 | 35,000 | 39,550 | 75,000 | |
Dec 14 2009 | SLXP | SALIX PHARMACEUTIC ... | LOGAN CAROLYN J | President & CEO | Buy | M | 1.13 | 35,000 | 39,550 | 665,581 | 630.6 K to 665.6 K (+5.55 %) |
Dec 11 2009 | SLXP | SALIX PHARMACEUTIC ... | DERBYSHIRE ADAM C | EVP Finance/CFO | Option Exercise | M | 1.13 | 5,000 | 5,667 | 0 | |
Dec 11 2009 | SLXP | SALIX PHARMACEUTIC ... | DERBYSHIRE ADAM C | EVP Finance/CFO | Sell | S | 23.10 | 5,000 | 115,500 | 108,371 | 113.4 K to 108.4 K (-4.41 %) |
Dec 11 2009 | SLXP | SALIX PHARMACEUTIC ... | DERBYSHIRE ADAM C | EVP Finance/CFO | Buy | M | 1.13 | 5,000 | 5,667 | 113,371 | 108.4 K to 113.4 K (+4.61 %) |
Nov 30 2009 | SLXP | SALIX PHARMACEUTIC ... | DERBYSHIRE ADAM C | EVP Finance/CFO | Option Exercise | M | 1.13 | 5,000 | 5,667 | 10,000 | |
Nov 30 2009 | SLXP | SALIX PHARMACEUTIC ... | DERBYSHIRE ADAM C | EVP Finance/CFO | Sell | S | 23.58 | 5,000 | 117,900 | 108,371 | 113.4 K to 108.4 K (-4.41 %) |
Nov 30 2009 | SLXP | SALIX PHARMACEUTIC ... | DERBYSHIRE ADAM C | EVP Finance/CFO | Buy | M | 1.13 | 5,000 | 5,667 | 113,371 | 108.4 K to 113.4 K (+4.61 %) |
Dec 02 2009 | SLXP | SALIX PHARMACEUTIC ... | DERBYSHIRE ADAM C | EVP Finance/CFO | Option Exercise | M | 1.13 | 5,000 | 5,667 | 5,000 | |
Dec 02 2009 | SLXP | SALIX PHARMACEUTIC ... | DERBYSHIRE ADAM C | EVP Finance/CFO | Sell | S | 23.37 | 5,000 | 116,850 | 108,371 | 113.4 K to 108.4 K (-4.41 %) |
Dec 02 2009 | SLXP | SALIX PHARMACEUTIC ... | DERBYSHIRE ADAM C | EVP Finance/CFO | Buy | M | 1.13 | 5,000 | 5,667 | 113,371 | 108.4 K to 113.4 K (+4.61 %) |
Nov 13 2009 | SLXP | SALIX PHARMACEUTIC ... | DERBYSHIRE ADAM C | EVP Finance/CFO | Option Exercise | M | 1.13 | 5,000 | 5,667 | 20,000 | |
Nov 13 2009 | SLXP | SALIX PHARMACEUTIC ... | DERBYSHIRE ADAM C | EVP Finance/CFO | Sell | S | 20.12 | 5,000 | 100,600 | 108,371 | 113.4 K to 108.4 K (-4.41 %) |
Nov 13 2009 | SLXP | SALIX PHARMACEUTIC ... | DERBYSHIRE ADAM C | EVP Finance/CFO | Buy | M | 1.13 | 5,000 | 5,667 | 113,371 | 108.4 K to 113.4 K (+4.61 %) |
Nov 19 2009 | SLXP | SALIX PHARMACEUTIC ... | DERBYSHIRE ADAM C | EVP Finance/CFO | Option Exercise | M | 1.13 | 5,000 | 5,667 | 15,000 | |
Nov 19 2009 | SLXP | SALIX PHARMACEUTIC ... | DERBYSHIRE ADAM C | EVP Finance/CFO | Sell | S | 21.05 | 5,000 | 105,250 | 108,371 | 113.4 K to 108.4 K (-4.41 %) |
Nov 19 2009 | SLXP | SALIX PHARMACEUTIC ... | DERBYSHIRE ADAM C | EVP Finance/CFO | Buy | M | 1.13 | 5,000 | 5,667 | 113,371 | 108.4 K to 113.4 K (+4.61 %) |
Nov 24 2009 | SLXP | SALIX PHARMACEUTIC ... | Reeth Mark D | Gen Counsel&VP Corp ... | Sell | S | 23.64 | 3,377 | 79,849 | 48,562 | 51.9 K to 48.6 K (-6.50 %) |
Oct 29 2009 | SLXP | SALIX PHARMACEUTIC ... | DERBYSHIRE ADAM C | EVP Finance/CFO | Option Exercise | M | 1.13 | 5,000 | 5,667 | 30,000 | |
Oct 29 2009 | SLXP | SALIX PHARMACEUTIC ... | DERBYSHIRE ADAM C | EVP Finance/CFO | Sell | S | 19.79 | 5,000 | 98,950 | 108,371 | 113.4 K to 108.4 K (-4.41 %) |
Oct 29 2009 | SLXP | SALIX PHARMACEUTIC ... | DERBYSHIRE ADAM C | EVP Finance/CFO | Buy | M | 1.13 | 5,000 | 5,667 | 113,371 | 108.4 K to 113.4 K (+4.61 %) |
Nov 06 2009 | SLXP | SALIX PHARMACEUTIC ... | DERBYSHIRE ADAM C | EVP Finance/CFO | Option Exercise | M | 1.13 | 5,000 | 5,667 | 25,000 | |
Nov 06 2009 | SLXP | SALIX PHARMACEUTIC ... | DERBYSHIRE ADAM C | EVP Finance/CFO | Sell | S | 19.85 | 84 | 1,667 | 108,371 | 108.5 K to 108.4 K (-0.08 %) |
Nov 06 2009 | SLXP | SALIX PHARMACEUTIC ... | DERBYSHIRE ADAM C | EVP Finance/CFO | Sell | S | 19.81 | 200 | 3,962 | 108,455 | 108.7 K to 108.5 K (-0.18 %) |
Nov 06 2009 | SLXP | SALIX PHARMACEUTIC ... | DERBYSHIRE ADAM C | EVP Finance/CFO | Sell | S | 19.80 | 200 | 3,960 | 108,655 | 108.9 K to 108.7 K (-0.18 %) |
Nov 06 2009 | SLXP | SALIX PHARMACEUTIC ... | DERBYSHIRE ADAM C | EVP Finance/CFO | Sell | S | 19.78 | 300 | 5,934 | 108,855 | 109.2 K to 108.9 K (-0.27 %) |
Nov 06 2009 | SLXP | SALIX PHARMACEUTIC ... | DERBYSHIRE ADAM C | EVP Finance/CFO | Sell | S | 19.77 | 96 | 1,898 | 109,155 | 109.3 K to 109.2 K (-0.09 %) |
Nov 06 2009 | SLXP | SALIX PHARMACEUTIC ... | DERBYSHIRE ADAM C | EVP Finance/CFO | Sell | S | 19.76 | 99 | 1,956 | 109,251 | 109.4 K to 109.3 K (-0.09 %) |
Nov 06 2009 | SLXP | SALIX PHARMACEUTIC ... | DERBYSHIRE ADAM C | EVP Finance/CFO | Sell | S | 19.75 | 99 | 1,955 | 109,350 | 109.4 K to 109.4 K (-0.09 %) |
Nov 06 2009 | SLXP | SALIX PHARMACEUTIC ... | DERBYSHIRE ADAM C | EVP Finance/CFO | Sell | S | 19.74 | 100 | 1,974 | 109,449 | 109.5 K to 109.4 K (-0.09 %) |
Nov 06 2009 | SLXP | SALIX PHARMACEUTIC ... | DERBYSHIRE ADAM C | EVP Finance/CFO | Sell | S | 19.73 | 100 | 1,973 | 109,549 | 109.6 K to 109.5 K (-0.09 %) |
Nov 06 2009 | SLXP | SALIX PHARMACEUTIC ... | DERBYSHIRE ADAM C | EVP Finance/CFO | Sell | S | 19.72 | 404 | 7,967 | 109,649 | 110.1 K to 109.6 K (-0.37 %) |
Nov 06 2009 | SLXP | SALIX PHARMACEUTIC ... | DERBYSHIRE ADAM C | EVP Finance/CFO | Sell | S | 19.71 | 300 | 5,913 | 110,053 | 110.4 K to 110.1 K (-0.27 %) |
Nov 06 2009 | SLXP | SALIX PHARMACEUTIC ... | DERBYSHIRE ADAM C | EVP Finance/CFO | Sell | S | 19.70 | 800 | 15,760 | 110,353 | 111.2 K to 110.4 K (-0.72 %) |
Nov 06 2009 | SLXP | SALIX PHARMACEUTIC ... | DERBYSHIRE ADAM C | EVP Finance/CFO | Sell | S | 19.69 | 805 | 15,850 | 111,153 | 112 K to 111.2 K (-0.72 %) |
Nov 06 2009 | SLXP | SALIX PHARMACEUTIC ... | DERBYSHIRE ADAM C | EVP Finance/CFO | Sell | S | 19.66 | 200 | 3,932 | 111,958 | 112.2 K to 112 K (-0.18 %) |
Nov 06 2009 | SLXP | SALIX PHARMACEUTIC ... | DERBYSHIRE ADAM C | EVP Finance/CFO | Sell | S | 19.62 | 600 | 11,772 | 112,158 | 112.8 K to 112.2 K (-0.53 %) |
Nov 06 2009 | SLXP | SALIX PHARMACEUTIC ... | DERBYSHIRE ADAM C | EVP Finance/CFO | Sell | S | 19.60 | 613 | 12,015 | 112,758 | 113.4 K to 112.8 K (-0.54 %) |
Nov 06 2009 | SLXP | SALIX PHARMACEUTIC ... | DERBYSHIRE ADAM C | EVP Finance/CFO | Buy | M | 1.13 | 5,000 | 5,667 | 113,371 | 108.4 K to 113.4 K (+4.61 %) |
Oct 23 2009 | SLXP | SALIX PHARMACEUTIC ... | DERBYSHIRE ADAM C | EVP Finance/CFO | Option Exercise | M | 1.13 | 5,000 | 5,667 | 35,000 | |
Oct 23 2009 | SLXP | SALIX PHARMACEUTIC ... | DERBYSHIRE ADAM C | EVP Finance/CFO | Sell | S | 21.00 | 5,000 | 105,000 | 108,371 | 113.4 K to 108.4 K (-4.41 %) |
Oct 23 2009 | SLXP | SALIX PHARMACEUTIC ... | DERBYSHIRE ADAM C | EVP Finance/CFO | Buy | M | 1.13 | 5,000 | 5,667 | 113,371 | 108.4 K to 113.4 K (+4.61 %) |
Oct 14 2009 | SLXP | SALIX PHARMACEUTIC ... | DERBYSHIRE ADAM C | EVP Finance/CFO | Option Exercise | M | 1.13 | 5,000 | 5,667 | 40,000 | |
Oct 14 2009 | SLXP | SALIX PHARMACEUTIC ... | DERBYSHIRE ADAM C | EVP Finance/CFO | Sell | S | 22.89 | 5,000 | 114,450 | 108,371 | 113.4 K to 108.4 K (-4.41 %) |
Oct 14 2009 | SLXP | SALIX PHARMACEUTIC ... | DERBYSHIRE ADAM C | EVP Finance/CFO | Buy | M | 1.13 | 5,000 | 5,667 | 113,371 | 108.4 K to 113.4 K (+4.61 %) |
Oct 08 2009 | SLXP | SALIX PHARMACEUTIC ... | DERBYSHIRE ADAM C | EVP Finance/CFO | Option Exercise | M | 1.13 | 5,000 | 5,667 | 45,000 | |
Oct 08 2009 | SLXP | SALIX PHARMACEUTIC ... | DERBYSHIRE ADAM C | EVP Finance/CFO | Sell | S | 23.89 | 5,000 | 119,450 | 108,371 | 113.4 K to 108.4 K (-4.41 %) |
Oct 08 2009 | SLXP | SALIX PHARMACEUTIC ... | DERBYSHIRE ADAM C | EVP Finance/CFO | Buy | M | 1.13 | 5,000 | 5,667 | 113,371 | 108.4 K to 113.4 K (+4.61 %) |
Oct 01 2009 | SLXP | SALIX PHARMACEUTIC ... | DERBYSHIRE ADAM C | EVP Finance/CFO | Option Exercise | M | 1.13 | 5,000 | 5,667 | 50,000 | |
Oct 01 2009 | SLXP | SALIX PHARMACEUTIC ... | DERBYSHIRE ADAM C | EVP Finance/CFO | Sell | S | 21.04 | 5,000 | 105,200 | 108,371 | 113.4 K to 108.4 K (-4.41 %) |
Oct 01 2009 | SLXP | SALIX PHARMACEUTIC ... | DERBYSHIRE ADAM C | EVP Finance/CFO | Buy | M | 1.13 | 5,000 | 5,667 | 113,371 | 108.4 K to 113.4 K (+4.61 %) |
Sep 24 2009 | SLXP | SALIX PHARMACEUTIC ... | DERBYSHIRE ADAM C | EVP Finance/CFO | Option Exercise | M | 1.13 | 5,000 | 5,667 | 55,000 | |
Sep 24 2009 | SLXP | SALIX PHARMACEUTIC ... | DERBYSHIRE ADAM C | EVP Finance/CFO | Sell | S | 20.73 | 5,000 | 103,650 | 108,371 | 113.4 K to 108.4 K (-4.41 %) |
Sep 24 2009 | SLXP | SALIX PHARMACEUTIC ... | DERBYSHIRE ADAM C | EVP Finance/CFO | Buy | M | 1.13 | 5,000 | 5,667 | 113,371 | 108.4 K to 113.4 K (+4.61 %) |
Sep 16 2009 | SLXP | SALIX PHARMACEUTIC ... | DERBYSHIRE ADAM C | EVP Finance/CFO | Option Exercise | M | 1.13 | 5,000 | 5,667 | 60,000 | |
Sep 16 2009 | SLXP | SALIX PHARMACEUTIC ... | DERBYSHIRE ADAM C | EVP Finance/CFO | Sell | S | 19.80 | 5,000 | 99,000 | 108,371 | 113.4 K to 108.4 K (-4.41 %) |
Sep 16 2009 | SLXP | SALIX PHARMACEUTIC ... | DERBYSHIRE ADAM C | EVP Finance/CFO | Buy | M | 1.13 | 5,000 | 5,667 | 109,371 | 104.4 K to 109.4 K (+4.79 %) |
Sep 15 2009 | SLXP | SALIX PHARMACEUTIC ... | LOGAN CAROLYN J | President & CEO | Option Exercise | M | 1.13 | 10,000 | 11,300 | 110,000 | |
Sep 15 2009 | SLXP | SALIX PHARMACEUTIC ... | LOGAN CAROLYN J | President & CEO | Sell | S | 20.67 | 10,000 | 206,742 | 630,581 | 640.6 K to 630.6 K (-1.56 %) |
Sep 15 2009 | SLXP | SALIX PHARMACEUTIC ... | LOGAN CAROLYN J | President & CEO | Buy | M | 1.13 | 10,000 | 11,300 | 640,581 | 630.6 K to 640.6 K (+1.59 %) |
Sep 10 2009 | SLXP | SALIX PHARMACEUTIC ... | Flynn James E | 10% Owner | Sell | S | 13.16 | 133,445 | 1,756,136 | 2,941,480 | 3.1 M to 2.9 M (-4.34 %) |
Sep 10 2009 | SLXP | SALIX PHARMACEUTIC ... | Flynn James E | 10% Owner | Sell | S | 13.16 | 66,555 | 875,864 | 1,928,520 | 2 M to 1.9 M (-3.34 %) |
Sep 10 2009 | SLXP | SALIX PHARMACEUTIC ... | Flynn James E | 10% Owner | Sell | S | 13.06 | 33,361 | 435,695 | 3,074,925 | 3.1 M to 3.1 M (-1.07 %) |
Sep 10 2009 | SLXP | SALIX PHARMACEUTIC ... | Flynn James E | 10% Owner | Sell | S | 13.06 | 16,639 | 217,305 | 1,995,075 | 2 M to 2 M (-0.83 %) |
Sep 10 2009 | SLXP | SALIX PHARMACEUTIC ... | Flynn James E | 10% Owner | Sell | S | 13.01 | 200,168 | 2,604,186 | 3,108,286 | 3.3 M to 3.1 M (-6.05 %) |
Sep 10 2009 | SLXP | SALIX PHARMACEUTIC ... | Flynn James E | 10% Owner | Sell | S | 13.01 | 99,832 | 1,298,814 | 2,011,714 | 2.1 M to 2 M (-4.73 %) |
Sep 10 2009 | SLXP | SALIX PHARMACEUTIC ... | Flynn James E | 10% Owner | Sell | S | 13.49 | 64,720 | 873,073 | 3,308,454 | 3.4 M to 3.3 M (-1.92 %) |
Sep 10 2009 | SLXP | SALIX PHARMACEUTIC ... | Flynn James E | 10% Owner | Sell | S | 13.49 | 32,280 | 435,457 | 2,111,546 | 2.1 M to 2.1 M (-1.51 %) |
Sep 10 2009 | SLXP | SALIX PHARMACEUTIC ... | Flynn James E | 10% Owner | Sell | S | 13.06 | 41,980 | 548,259 | 3,373,174 | 3.4 M to 3.4 M (-1.23 %) |
Sep 10 2009 | SLXP | SALIX PHARMACEUTIC ... | Flynn James E | 10% Owner | Sell | S | 13.06 | 20,937 | 273,437 | 2,143,826 | 2.2 M to 2.1 M (-0.97 %) |
Sep 10 2009 | SLXP | SALIX PHARMACEUTIC ... | Flynn James E | 10% Owner | Sell | S | 13.32 | 22,782 | 303,456 | 3,415,154 | 3.4 M to 3.4 M (-0.66 %) |
Sep 10 2009 | SLXP | SALIX PHARMACEUTIC ... | Flynn James E | 10% Owner | Sell | S | 13.32 | 11,361 | 151,329 | 2,164,763 | 2.2 M to 2.2 M (-0.52 %) |
Sep 10 2009 | SLXP | SALIX PHARMACEUTIC ... | Flynn James E | 10% Owner | Sell | S | 12.98 | 145,704 | 1,891,238 | 3,437,936 | 3.6 M to 3.4 M (-4.07 %) |
Sep 10 2009 | SLXP | SALIX PHARMACEUTIC ... | Flynn James E | 10% Owner | Sell | S | 12.96 | 25,000 | 324,000 | 3,583,640 | 3.6 M to 3.6 M (-0.69 %) |
Sep 10 2009 | SLXP | SALIX PHARMACEUTIC ... | Flynn James E | 10% Owner | Sell | S | 12.98 | 111,189 | 1,443,233 | 3,608,640 | 3.7 M to 3.6 M (-2.99 %) |
Sep 09 2009 | SLXP | SALIX PHARMACEUTIC ... | DERBYSHIRE ADAM C | EVP Finance/CFO | Option Exercise | M | 1.13 | 5,000 | 5,667 | 65,000 | |
Sep 09 2009 | SLXP | SALIX PHARMACEUTIC ... | DERBYSHIRE ADAM C | EVP Finance/CFO | Sell | S | 12.92 | 5,000 | 64,600 | 108,371 | 113.4 K to 108.4 K (-4.41 %) |
Sep 09 2009 | SLXP | SALIX PHARMACEUTIC ... | DERBYSHIRE ADAM C | EVP Finance/CFO | Buy | M | 1.13 | 5,000 | 5,667 | 109,371 | 104.4 K to 109.4 K (+4.79 %) |
Sep 04 2009 | SLXP | SALIX PHARMACEUTIC ... | DERBYSHIRE ADAM C | EVP Finance/CFO | Option Exercise | M | 1.13 | 1,000 | 1,133 | 70,000 | |
Sep 04 2009 | SLXP | SALIX PHARMACEUTIC ... | DERBYSHIRE ADAM C | EVP Finance/CFO | Option Exercise | M | 1.13 | 1,000 | 1,133 | 71,000 | |
Sep 04 2009 | SLXP | SALIX PHARMACEUTIC ... | DERBYSHIRE ADAM C | EVP Finance/CFO | Option Exercise | M | 1.13 | 1,000 | 1,133 | 72,000 | |
Sep 04 2009 | SLXP | SALIX PHARMACEUTIC ... | DERBYSHIRE ADAM C | EVP Finance/CFO | Sell | S | 12.45 | 1,000 | 12,450 | 108,371 | 109.4 K to 108.4 K (-0.91 %) |
Sep 04 2009 | SLXP | SALIX PHARMACEUTIC ... | DERBYSHIRE ADAM C | EVP Finance/CFO | Buy | M | 1.13 | 1,000 | 1,133 | 109,371 | 108.4 K to 109.4 K (+0.92 %) |
Sep 04 2009 | SLXP | SALIX PHARMACEUTIC ... | DERBYSHIRE ADAM C | EVP Finance/CFO | Sell | S | 12.24 | 100 | 1,224 | 108,371 | 108.5 K to 108.4 K (-0.09 %) |
Sep 04 2009 | SLXP | SALIX PHARMACEUTIC ... | DERBYSHIRE ADAM C | EVP Finance/CFO | Sell | S | 12.22 | 900 | 10,998 | 108,471 | 109.4 K to 108.5 K (-0.82 %) |